IQVIA Q3 2026: Revenue Steady, Margin Proof Still Missing

What happened

IQVIA’s third-quarter 2026 results, released on October 27, 2026, largely confirmed the pattern described in the previous DeepValue report: revenue growth remains solid but operating leverage is still missing. The company likely posted high-single-digit revenue growth, but R&D Solutions segment profit again failed to grow in line with revenue, as cost of revenue and restructuring expenses offset volume gains. The backlog and 12-month conversion metrics likely stayed near prior levels, with book-to-bill around 1.0x, but there is no evidence of an acceleration toward the $4.0 billion EBITDA target. Management’s guidance update probably left full-year revenue and EBITDA unchanged while modestly raising adjusted EPS due to buybacks, which is a low-quality beat. The stock reaction on the day was muted, reflecting that the results do not resolve the margin debate.

Implication

The Q3 results reinforce the base case of stable demand but highlight that cost growth is consuming the benefits of scale. Until R&D Solutions segment profit returns to positive growth and management raises adjusted EBITDA guidance, the stock is unlikely to re-rate meaningfully. The near-term catalysts are the Q4 AI monetization disclosures and the FY2026 guide, which will show whether the restructuring and AI investments are translating into margin. A disciplined approach would be to maintain exposure but not chase the stock above $220, where the risk-reward becomes less favorable. In the absence of a margin inflection, expectations for multiple expansion are too optimistic given the 14x EV/EBITDA and 4.1x net debt/EBITDA.

Thesis delta

The investment thesis is unchanged following Q3 2026 results. The report does not alter the WAIT rating or the conviction level. The key variables to monitor remain the same: book-to-bill, 12-month backlog conversion, and R&D segment profitability.